Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
Main Authors: | Matteo Fassan, Chiara Cremolini, Matteo Benelli, Elisa Fontana, Filippo Pagani, Daniele Rossini, Giovanni Fucà, Adele Busico, Elena Conca, Samantha Di Donato, Fotios Loupakis, Marta Schirripa, Sara Lonardi, Beatrice Borelli, Elena Ongaro, Katherine Eason, Mariaelena Casagrande, Anguraj Sadanandam, Filippo de Braud, Alfredo Falcone |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-04-01
|
Series: | ESMO Open |
Online Access: | https://esmoopen.bmj.com/content/4/2/e000299corr1.full |
Similar Items
-
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
by: Francesca Ligorio, et al.
Published: (2022-03-01) -
polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance
by: Katherine Eason, et al.
Published: (2018-05-01) -
<i>HER2–CDH1</i> Interaction via Wnt/B-Catenin Is Associated with Patients’ Survival in HER2-Positive Metastatic Gastric Adenocarcinoma
by: Valli De Re, et al.
Published: (2022-02-01) -
BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017) -
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
by: Irene Gullo, et al.
Published: (2015-02-01)